NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, Forecast & News

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Protalix Biotherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.20. The firm earned $14.25 million during the quarter, compared to the consensus estimate of $11.60 million. During the same period in the prior year, the firm earned ($1.00) EPS. View Protalix Biotherapeutics' Earnings History.

Protalix Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Protalix Biotherapeutics.

1 Wall Street analysts have issued 12 month price targets for Protalix Biotherapeutics' shares. Their forecasts range from $30.00 to $30.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $30.00 in the next year. This suggests a possible upside of 667.3% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics.

News stories about PLX stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Protalix Biotherapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Protalix Biotherapeutics.

Protalix Biotherapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 373,000 shares, an increase of 39.8% from the January 15th total of 266,900 shares. Based on an average daily trading volume, of 132,800 shares, the days-to-cover ratio is currently 2.8 days. Approximately 2.6% of the company's stock are short sold. View Protalix Biotherapeutics' Current Options Chain.

Some companies that are related to Protalix Biotherapeutics include Antibe Therapeutics (ATE), Helix Biopharma (HBP), Fennec Pharmaceuticals (FRX), Enochian Biosciences (ENOB), Senesco Technologies (ELOX), CorMedix (CRMD), CorMedix (CRMD), Immutep (IMM), Burcon NutraScience (BU), Ampliphi Biosciences (APHB), 22nd Century Group (XXII), MediGene (MDG1), OncoCyte (OCX), OncoCyte (OCX) and Novoheart (NVH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), BIOLINERX LTD/S (BLRX), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Nabriva Therapeutics (NBRV), Novavax (NVAX), TrovaGene (TROV) and Melinta Therapeutics (MLNT).

Protalix Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.10%), California Public Employees Retirement System (0.54%), Jane Street Group LLC (0.22%) and SG Americas Securities LLC (0.15%). View Institutional Ownership Trends for Protalix Biotherapeutics.

PLX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, California Public Employees Retirement System and SG Americas Securities LLC. View Insider Buying and Selling for Protalix Biotherapeutics.

PLX stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View Insider Buying and Selling for Protalix Biotherapeutics.

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PLX stock can currently be purchased for approximately $3.91.

Protalix Biotherapeutics has a market capitalization of $58.02 million. Protalix Biotherapeutics employs 184 workers across the globe.View Additional Information About Protalix Biotherapeutics.

The official website for Protalix Biotherapeutics is http://www.protalix.com/.

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.